These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25406647)

  • 21. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
    Wolf M; Korja M; Karhu R; Edgren H; Kilpinen S; Ojala K; Mousses S; Kallioniemi A; Haapasalo H
    BMC Cancer; 2010 May; 10():181. PubMed ID: 20444257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease.
    Grau E; Martinez F; Orellana C; Canete A; Yañez Y; Oltra S; Noguera R; Hernandez M; Bermúdez JD; Castel V
    Mol Carcinog; 2011 Mar; 50(3):153-62. PubMed ID: 21104989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXP1 is a regulator of quiescence in healthy human CD4
    Garaud S; Roufosse F; De Silva P; Gu-Trantien C; Lodewyckx JN; Duvillier H; Dedeurwaerder S; Bizet M; Defrance M; Fuks F; Bex F; Willard-Gallo K
    Eur J Immunol; 2017 Jan; 47(1):168-179. PubMed ID: 27861791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas.
    Fox SB; Brown P; Han C; Ashe S; Leek RD; Harris AL; Banham AH
    Clin Cancer Res; 2004 May; 10(10):3521-7. PubMed ID: 15161711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification.
    Misawa A; Inoue J; Sugino Y; Hosoi H; Sugimoto T; Hosoda F; Ohki M; Imoto I; Inazawa J
    Cancer Res; 2005 Nov; 65(22):10233-42. PubMed ID: 16288011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
    Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
    Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
    Djos A; Martinsson T; Kogner P; Carén H
    Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-promoter DNA hypermethylation of Zygote Arrest 1 (ZAR1) in neuroblastomas.
    Sugito K; Kawashima H; Yoshizawa S; Uekusa S; Hoshi R; Furuya T; Kaneda H; Hosoda T; Konuma N; Masuko T; Ohashi K; Ikeda T; Koshinaga T; Tomita R; Shinojima Y; Fujiwara K; Watanabe T; Held WA; Nagase H
    J Pediatr Surg; 2013 Apr; 48(4):782-8. PubMed ID: 23583134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma.
    Lau DT; Hesson LB; Norris MD; Marshall GM; Haber M; Ashton LJ
    Clin Cancer Res; 2012 Oct; 18(20):5690-700. PubMed ID: 22929802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
    Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
    Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation.
    Parodi F; Carosio R; Ragusa M; Di Pietro C; Maugeri M; Barbagallo D; Sallustio F; Allemanni G; Pistillo MP; Casciano I; Forlani A; Schena FP; Purrello M; Romani M; Banelli B
    Biochim Biophys Acta; 2016 Dec; 1859(12):1502-1514. PubMed ID: 27751904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.